0 419

Cited 8 times in

Targeting MicroRNAs Involved in the BDNF Signaling Impairment in Neurodegenerative Diseases

DC Field Value Language
dc.contributor.author신재일-
dc.date.accessioned2017-10-26T07:54:05Z-
dc.date.available2017-10-26T07:54:05Z-
dc.date.issued2016-
dc.identifier.issn1535-1084-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/152664-
dc.description.abstractNeurodegenerative diseases are becoming an ever-increasing problem in aging populations. Low levels of brain-derived neurotrophic factor (BDNF) have previously been associated with the pathogenesis of numerous neurodegenerative diseases. Recently, microRNAs (miRNAs) have been proposed as potential novel therapeutic targets for treating various diseases of the central nervous system (CNS), and interestingly, few studies have reported several miRNAs that downregulate the expression levels of BDNF. However, substantial challenges exist when attempting to translate these findings into practical anti-miRNA therapeutics, especially when the targets remain inside the CNS. Thus, in this review, we summarize the specific molecular mechanisms by which several miRNAs negatively modulate the expressions of BDNF, address the potential clinical difficulties that can be faced during the development of anti-miRNA-based therapeutics and propose strategies to overcome these challenges.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherHumana Press-
dc.relation.isPartOfNEUROMOLECULAR MEDICINE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleTargeting MicroRNAs Involved in the BDNF Signaling Impairment in Neurodegenerative Diseases-
dc.typeArticle-
dc.publisher.locationUnited States-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Pediatrics-
dc.contributor.googleauthorHwa Jeong You-
dc.contributor.googleauthorJae Hyon Park-
dc.contributor.googleauthorHelios Pareja-Galeano-
dc.contributor.googleauthorAlejandro Lucia-
dc.contributor.googleauthorJae Il Shin-
dc.identifier.doi10.1007/s12017-016-8407-9-
dc.contributor.localIdA02142-
dc.relation.journalcodeJ03032-
dc.identifier.eissn1559-1174-
dc.relation.journalsince2002-
dc.identifier.pmid27209362-
dc.identifier.urlhttps://link.springer.com/article/10.1007%2Fs12017-016-8407-9-
dc.contributor.alternativeNameShin, Jae Il-
dc.contributor.affiliatedAuthorShin, Jae Il-
dc.citation.volume18-
dc.citation.number4-
dc.citation.startPage540-
dc.citation.endPage550-
dc.identifier.bibliographicCitationNEUROMOLECULAR MEDICINE, Vol.18(4) : 540-550, 2016-
dc.date.modified2017-10-24-
dc.identifier.rimsid39673-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.